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Abstract 
Background  
There is currently insufficient evidence to support the use of lipid-lowering drug 
treatment (LLT) for primary prevention of cardiovascular disease (CVD) in the 
elderly. 
Objectives 
We examined the relationship of early initiation of LLT with short- and long-term all-
cause and CVD mortality in persons older than 65 years in this post-hoc study from 
the Second Australian National Blood Pressure study (ANBP2). 
Methods 
In- and post-trial observational study. 4257 hypertensive participants aged 65 to 84 
years within Australian family practices were randomized to an angiotensin 
converting enzyme-inhibitor or a diuretic treatment group. After excluding 
participants with a prior history of CVD, the cohort was stratified into ‘LLT’ and ‘no 
LLT’ subgroups based on LLT status at randomization. 
Results 
At randomization the participants had a mean age of 72 years, average blood 
pressure (BP) of 168/91 mmHg and estimated 5-year CVD risk of 18.7 ± 8.3%. In the 
overall study population, the association of LLT with long-term (11-years) all-cause 
and non-CVD mortality was significant [HR 0.78 (95% CI 0.66-0.92, p=0.003) and 
HR 0.70 (95% CI 0.54-0.90, p=0.006) respectively]. Magnitudes of the association of 
LLT with long-term mortality and the association with short-term mortality were 
similar, however, no statistically significant association with short-term mortality was 
observed. In the subgroup analysis by baseline 5-year CVD risk, LLT participants in 
the highest risk tertile had a substantially lower relative risk for short-term all-cause 
mortality (HR 0.31, 95% CI 0.13-0.71, p for interaction 0.02), compared to those with 
lower estimated CVD risk. All analyses were adjusted for baseline and in-trial 
characteristics. 
Conclusion 
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Our study showed a strong association between LLT and reduced long-term all-
cause mortality. Thus, our findings support recommendations of the use of LLT in 
patients over 65, particularly those with high CVD risk who were more likely to obtain 
additional benefits in the short-term. The findings also suggested that mortality 
benefits of LLT for the elderly may take longer to become evident. 
Highlights 
 Our study supports the use of LLT for primary prevention of CVD in the 
elderly. 
 LLT was associated with a reduced long-term all-cause mortality. 
 High risk participants obtained further benefits for short-term all-cause 
mortality. 
Key Words: lipid-lowering drug treatment, cardiovascular disease, primary 
prevention, absolute cardiovascular risk, elderly. 
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Background 
The global population is ageing. In 2015 there were 617 million (8.5%) people 
aged over 65 years and this is likely to reach 1.6 billion (17%) by 2050 1. 
Cardiovascular disease (CVD) remains the leading burden of disease in this age 
group, being 30% of the total 2. Lipid-lowering drug treatment (LLT), particularly 
statins, plays a key role in the prevention of CVD 3-5. More than 40% of the 
Australian and US populations aged 75 and over are currently taking LLT 6,7 and this 
number is projected to grow as most of the LLTs come off patent and are therefore 
available at lower cost.  
Most of the evidence for benefits from the use of LLT in those 65 years or 
over are from trials of secondary prevention of CVD or in mixed populations of those 
with and without a previous history of CVD 8-16 whereas insufficient evidence is 
available to support the use of LLT for primary prevention in the elderly 17-20. A 
systematic review and meta-analysis by Savarese et al 21 related predominantly to 
primary prevention reported no significant mortality benefit of statin treatment in 
individuals aged 65 and over, although there were significant reductions in 
myocardial infarction (MI) and stroke. The average follow-up in the studies in this 
analysis was 3.5 years (range: 1.0 – 5.2 years) 9,13-16,22. 
A prospective cohort study with 7.3 years follow-up 23 found substantial effects 
of early statin use (on-treatment versus no treatment at baseline) on major CVD 
events and all-cause mortality in the elderly (≥ 65 years) without CVD at baseline. 
This result stands despite a possible dilution of effects due to 13% of non-drug users 
at baseline initiating treatment during the study. In contrast, another elderly cohort 24 
with median follow-up at 9.1 years found no benefits for CVD or CHD events except 
stroke. Evidence for both short- and long-term benefits of LLT in older adults thus 
remains inconsistent. From patients’ perspectives, other considerations in this age 
group impacting on chronic drug therapy are drug adherence, the possibility of 
adverse drug effects and the potential for consideration of medication discontinuation 
when other issues such as frailty and life expectancy become dominant 25,26. In this 
current post-hoc study in a cohort of hypertensive elderly from the Second Australian 
National Blood Pressure study (ANBP2)27, we have examined the relationship 
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between the use of LLT at randomization and short- (4 year) and long-term (11 year) 
all-cause and CVD mortality in those aged 65 years or over. 
Materials and methods 
We conducted a post-hoc analysis relating to a cohort from the Second 
Australian National Blood Pressure study (ANBP2)27. ANBP2 had an open-labelled 
design with blinded end-point assessment. Participants aged 65-84 years at 
enrolment were randomized into an angiotensin-converting enzyme treatment group 
(enalapril recommended) or a thiazide diuretic treatment group (hydrochlorothiazide 
recommended) within Australian family practices. At entry, eligible participants had 
an average randomized blood pressure (BP) of 160/90 mmHg or over. Short-term 
mortality outcomes were followed for a median 4.1 years (from 1995 to 2001) as 
described by Wing et al 27. A blinded independent endpoint committee adjudicated all 
study endpoints. An extended observation relating to survival status was conducted 
to a median 10.8 years (4.1-years in-trial and 6.7 years post-trial) using linkage to 
the Australian National Death Index as described by Nelson et al 28 to investigate 
longer term all-cause or CVD mortality. In this study, fatal cardiovascular events 
were comprised of sudden cardiac deaths, fatal stroke, fatal myocardial infarction, 
and ‘other’ cardiovascular causes of death. 
To focus on primary prevention we excluded participants who had had 
previous CVD events at baseline (n=705) and those who were initiated on LLT 
(n=1292) during the clinical trial period because we were uncertain whether they 
were prescribed LLT due to a CVD occurrence or an increased cholesterol level. 
Participants were re-stratified by LLT status at entry. Subsequently, we compared 
the outcomes between those who were on LLT (LLT group) and those who were not 
(no LLT) at randomization (baseline) regardless of their randomized treatment. 
Subgroup by CVD risk 
To investigate how the effect of LLT was affected by baseline CVD risk, we 
performed a subgroup analysis stratified by tertile of 5-year predicted CVD risk score 
at entry. The risk score was calculated by the Framingham absolute risk equation as 
used in the Australian National Vascular Disease Prevention Alliance (NVDPA) 
guideline 29. As per the guideline, participants were automatically scored at high risk 
(>15%) if they had systolic BP ≥ 180 mmHg and/or diastolic BP ≥ 110 mmHg, total 
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cholesterol > 7.5 mmol/l, diabetes and/or estimated glomerular filtration rate<45 
ml/min/1.73 m2. For participants over 75 years of age, the age value was set at 74 in 
the risk calculation. 
Statistical analysis 
The differences between the ‘LLT’ and ‘no LLT’ groups for baseline 
characteristics were tested by t-tests for continuous variables and Chi-square tests 
for categorical variables. Cox proportional hazard models were used to estimate the 
hazard ratios (HRs) and corresponding 95% confidence interval (CIs) for outcomes 
for participants in the ‘LLT’ group compared with those in ‘no LLT’ group. Participants 
were followed-up from entry to the time of event (deaths) or loss of vital status or the 
end of the follow-up (maximum 6 years for the short-term analysis and 14 years for 
the long-term analysis). Those who did not have an event throughout the observed 
time scale were considered as censored on 30 Sep 2001 for the short-term and 31 
Oct 2009 for the long-term follow-up phase. The proportional assumption was 
checked by a test for interaction of LLT group with time. All of the analyses were 
adjusted for baseline characteristics (age, sex, family history of CVD, non-HDL 
cholesterol, diabetes, anti-platelet use), in-trial characteristics (number of assigned 
in-trial BP lowering drugs), and clustered on the general practice clinic from which 
participants originated. Further adjustment models were tested in sensitivity analysis. 
In addition, we conducted subgroup analyses stratified by age, sex and diabetes at 
baseline to investigate the impacts of these factors on the association of LLT and 
mortality outcomes.  The Cox regression models were used to test for interaction of 
treatment in the subgroup analyses. The significance of treatment effect was set to 
0.05. Data management for all analyses was performed by using Stata version 12 for 
Windows.  
Results 
Patient characteristics 
Our study included 4257 out of the original ANBP2 cohort of 6083 participants, 
approximately 70% of the total ANBP2 cohort. As shown in table 1, at study entry, 
participants had a mean age of 72 years, mean BP of 168/91 mmHg, mean plasma 
total cholesterol of 5.5 ± 0.9 mmol/l and HDL cholesterol of 1.4 ± 0.5 mmol/l. 
Compared with the ‘no LLT’ group, more female and younger participants were on 
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LLT at baseline. Also, LLT participants were more likely to have a family history of 
CVD, diagnosed diabetes mellitus, and be on antiplatelet and previous BP lowering 
drug treatment. Although these participants were on LLT, they still had higher 
average plasma total cholesterol level and non-HDL cholesterol. This may be 
attributable either to insufficient adherence to LLT or to the non-specific treatment 
target recommended at the time (1995-2001) for primary prevention. In general, 
based on the estimated risk over 5-year, all participants were at high risk of CVD – 
mean risk: 18.7% ± 8.3% using the Anderson equation30 as per the Australian 
NVDPA guideline 29. The estimated CVD risk score of the no LLT group (18.9% ± 
8.3%) was slightly higher than the LLT group, suggesting that LLT was prescribed 
based on the participant’s cholesterol level, not on absolute CVD risk. 
Table 1. Baseline characteristics by lipid-lowering drug treatment. 
  
Total 
(N=4257) 
No LLT 
(n=3609) 
LLT 
(n=648) 
p-
value 
Age (mean ± SD in years)  72.0 ± 5.0 72.1 ± 5.0 71.0 ± 4.4 <0.001 
Female sex n (%)  2195  (51.6) 1789 (49.6) 406 (62.7) <0.001 
Current smoker n (%)  305 (7.2) 260 (7.2) 45 (6.9) 0.81 
Systolic BP at randomization 
 (mean ± SD, mmHg) 167.6 ± 12.6 167.7 ± 12.6 167.4 ± 12.3 
 
0.58 
Diastolic BP at randomization 
(mean ± SD, mmHg) 90.8 ± 8.1 90.8 ± 8.1 90.8 ± 7.9 
 
0.89 
Total cholesterol  
(mean ± SD, mmol/l) 5.5 ± 0.9 5.5 ± 0.9 5.8 ± 1.1 
 
<0.001 
HDL cholesterol   
(mean ± SD, mmol/l) 1.4 ± 0.5 1.4 ± 0.5 1.4 ± 0.5 
 
0.48 
Non-HDL cholesterol  
(mean ± SD, mmol/l) 4.2 ± 1.0 4.1 ±  0.9 4.4 ± 1.1 
 
<0.001 
BMI (mean ± SD, kg/m2) 27.0 ± 4.2 27.0 ±   4.2 27.2 ±   4.1 0.18 
5-year Framingham risk score 
(mean ± SD, %) 18.7 ± 8.3 18.9 ±8.3 17.8 ± 8.1 
 
<0.001 
Diabetes mellitus n (%) 275 (6.5) 217 (6.0) 58 (9.0) 0.01 
Waist circumference  
(mean ± SD, cm) 94.4 ± 12.1 94.6 ± 12.2 93.6 ± 11.8 
 
0.07 
W-H ratio 0.90 ± 0.08 0.90 ± 0.08 0.89 ± 0.08 0.004 
8 
 
Current alcohol consumption n (%) 3126 (73.4) 2660 (73.7) 466 (71.9) 
 
0.34 
Physically active n (%) 3332 (78.3) 2815 (78.0) 517 (79.8) 0.31 
Education n (%) 
   
0.57 
Primary school 997 (23.4) 854 (23.7) 143 (22.1)  
High school not completed 1853 (43.5) 1560 (43.2) 293 (45.2)  
Competed high school or higher 1407 (33.1) 1195 (33.1) 212 (32.7)  
Socio-economic status n (%) 
   
0.66 
1st quartile (most advantaged) 1085 (25.5) 915 (25.4) 170 (26.2)  
2nd quartile 1151 (27.0) 969 (26.9) 182 (28.1)  
3rd quartile 1365 (32.1) 1171 (32.5) 194 (29.9)  
4th quartile (most disadvantage) 656 (15.4) 554 (15.4) 102 (15.7)  
Family history of CVD n (%)    <0.001 
Yes 1986 (46.7) 1604 (44.4) 382 (59.0)  
Unknown 496 (11.7) 423 (11.7) 73 (11.3)  
Random blood glucose  
(mean ± SD, mmol/l) 5.5 ± 1.8 5.5 ± 1.8 5.6 ± 1.9 
 
0.33 
Serum creatinine  
(mean ± SD, µmol/l) 90.8 ± 19.2 90.8 ± 19.2 90.8 ± 18.9 
 
0.96 
Antiplatelet use n (%) 433 (10.2) 341 (9.5) 92 (14.2) <0.001 
Previous BP lowering treatment  
n (%) 2556 (60.0) 2077 (57.6) 479 (73.9) 
 
<0.001 
 
 
LLT: lipid-lowering drug treatment, BP: blood pressure, HDL: high-density lipoprotein, BMI: 
body mass index, W-H ratio: waist-hip ratio, CVD: cardiovascular disease. Bold p<0.05 
For in-trial characteristics (Table 2), there was no significant difference 
between the number of ‘LLT’ and ‘no LLT’ participants randomized to either ACE-I or 
diuretic-based therapy. However, LLT participants were more likely to receive a 
higher number of randomized drugs and had a lower average on-treatment diastolic 
BP. 
Table 2. In-trial characteristics by LLT stratification. 
  
Total 
(N=4257) 
No LLT 
(n=3609) 
LLT 
(n=648) 
p-
value 
Randomized to ACE-I n (%) 2117 (49.7) 1782 (49.4) 355 (51.7) 0.28 
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BP lowering-drug compliance n (%) 1828 (67.2) 1532 (67.3) 296 (66.2) 
 
0.64 
Average on-treatment systolic BP  
(mean ± SD, mmHg) 145.6 ± 9.9 145.6 ± 9.9 145.4 ± 9.6 
0.49 
Average on-treatment diastolic BP  
(mean ± SD, mmHg) 80.8 ± 5.5 80.8 ± 5.5 80.3 ± 5.2 
 
0.02 
Number of assigned in-trial BP lowering drugs n (%) <0.001 
0 195 (4.6) 175 (4.9) 20 (3.1)  
1 2183 (51.6) 1902 (53.0) 281 (43.4)  
2 1640 (38.7) 1336 (37.3) 304 (46.7)  
≥3 216 (5.1) 174 (4.9) 42 (6.5)  
LLT: lipid-lowering drug treatment, ACE-I: Angiotensin Converting Enzyme-Inhibitor, BP: 
blood pressure.  Bold p<0.05 
Association of LLT and mortality in the total cohort  
263 deaths (106 CVD deaths including 13 fatal myocardial infarction, 28 fatal 
stroke and 65 other CVD deaths) occurred during the in-trial period (median 4.1 
years/’short-term’). These numbers increased to an overall 1250 deaths (622 CVD 
deaths including 124 fatal myocardial infarction, 122 fatal stroke and 376 other CVD 
deaths) by the end of the extended phase (median 10.8 years/’long-term’). 
Accumulative incidences of events according to LLT were presented in KM curves in 
figure 1 of the supplementary material.    
In the long-term (10.8 years), LLT participants had a significantly lower 
adjusted risk of all-cause mortality HR 0.78 (95% CI 0.66-0.92, p=0.003). Noticeably, 
most of the survival benefits were attributable to the effects on long-term non-CVD 
deaths HR 0.70 (95% CI 0.54-0.90, p=0.006), particularly cancer deaths HR 0.62 
(95% CI 0.44-0.88, p=0.007) (Table 3). Also, magnitudes of the association of LLT 
with long-term mortality and the association with short-term mortality were similar, 
however, no statistically significant association on short-term mortality was observed 
(Table 3 and 4).  In terms of CVD mortality, there was no significant difference 
between the LLT and no LLT groups in either the short (HR 0.86, 95% CI 0.46-1.61) 
or long term (HR 0.87, 95% CI 0.68-1.11). 
Table 3. Association between LLT and long-term mortality in tertiles by estimated 5-year 
CVD risk and in the total cohort. 
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Number of 
event % (n) 
Event (rate 
per 1000 
person-year) Univariate Adjusted * 
Tertiles by estimated 
5-year CVD risk 
 
LLT 
No 
LLT HR (95%CI) HR (95%CI) 
All-cause mortality 
     
1st tertile (2-14.5%)  7.0 (297) 11.5 22.5 0.51 (0.35-0.74) 0.64 (0.44-0.94) 
2nd tertile (14.5-22.6%) 9.3 (398) 21.7 29.6 0.72 (0.53-0.98) 0.85 (0.62-1.16) 
3rd tertile (22.6-59.8%)  13.1 (557) 30.7 43.3 0.70 (0.53-0.91) 0.85 (0.65-1.11) 
Total  29.4 (1252) 20.6 31.6 0.64 (0.54 - 0.76) 0.78 (0.66-0.92) 
p for interaction - - - 0.29 0.29 
CVD mortality    
  
1st tertile (2-14.5%)  3.3 (141) 5.9 10.5 0.56 (0.33-0.95) 0.74 (0.43-1.26) 
2nd tertile (14.5-22.6%) 4.6 (196) 10.9 14.5 0.74 (0.48-1.14) 0.86 (0.53-1.38) 
3rd tertile (22.6-59.8%)  6.6 (282) 17.9 21.4 0.82 (0.58-1.16) 0.98 (0.69-1.38) 
Total  14.5 (619) 11.1 15.4 0.71 (0.56 - 0.91) 0.87 (0.68-1.11) 
p for interaction - - - 0.5 0.46 
Cancer death    
  
1st tertile (2-14.5%)  2.0 (87) 2.4 6.8 0.35 (0.15-0.80) 0.40 (0.17-0.93) 
2nd tertile (14.5-22.6%) 2.9 (125) 7.1 9.3 0.76 (0.44-1.29) 0. 86(0.50-1.47) 
3rd tertile (22.6-59.8%)  3.7 (157) 6.9 12.5 0.55 (0.32-0.95) 0.62 (0.35-1.08) 
Total  8.7 (369) 5.3 9.5 0.55 (0.39 - 0.78) 0.62 (0.44-0.88) 
p for interaction - - - 0.27 0.28 
Non-CVD death    
  
1st tertile (2-14.5%)  3.7 (156) 5.5 11.9 0.46 (0.27-0.80) 0.57 (0.33-0.98) 
2nd tertile (14.5-22.6%) 4.7 (202) 10.9 15.1 0.71 (0.46-1.09) 0.84 (0.55-1.30) 
3rd tertile (22.6-59.8%)  6.5 (275) 12.9 21.8 0.58 (0.39-0.87) 0.72 (0.48-1.08) 
Total  14.9 (633) 9.5 16.2 0.57 (0.44-0.74) 0.70 (0.54-0.90) 
p for interaction - - - 0.47 0.48 
LLT: lipid-lowering treatment, CVD: cardiovascular disease. * Age, sex, family history of 
CVD, non-HDL-C, diabetes, anti-platelet use, clustering effect by general practice, number of 
assigned in-trial BP lowering drugs. Bold p<0.05. 
Table 4. Association between LLT and short-term mortality in tertiles by estimated 5-year 
CVD risk and in the total cohort. 
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Number 
of event 
% (n) 
Event (rate per 
1000 person-
year) Univariate Adjusted * 
Tertiles by estimated 
5-year CVD risk 
 
LLT No LLT HR (95%CI) HR (95%CI) 
All-cause mortality           
1st tertile (2-14.5%)  1.2 (52) 7.0 9.3 0.76 (0.34-1.67) 0.92 (0.41-2.07) 
2nd tertile (14.5-22.6%) 1.8 (76) 14.7 12.5 1.17 (0.64-2.12) 1.39 (0.74-2.60) 
3rd tertile (22.6-59.8%)  3.1 (134) 6.9 24.9 0.28 (0.12-0.64) 0.32 (0.14-0.75) 
Total  6.2 (262) 9.4 15.7 0.60 (0.40-0.90) 0.71 (0.47-1.07) 
p for interaction - - - 0.01 0.02 
CVD mortality  
    
1st tertile (2-14.5%)  0.4 (15) 2.0 2.8 0.70 (0.16-3.08) 1.12 (0.23-5.39) 
2nd tertile (14.5-22.6%) 0.8 (32) 7.9 5.1 1.54 (0.67-3.56) 1.78 (0.71-4.47) 
3rd tertile (22.6-59.8%)  1.3 (57) 3.5 10.4 0.33 (0.10-1.07) 0.35 (0.11-1.14) 
Total  2.4 (104) 4.3 6.2 0.71 (0.39 - 1.29) 0.86 (0.46-1.61) 
p for interaction - - - 0.09 0.1 
Cancer death  
    
1st tertile (2-14.5%)  0.5 (23) 3.0 4.0 0.74 (0.22-2.49) 0.77 (0.23-2.55) 
2nd tertile (14.5-22.6%) 0.8 (35) 5.6 5.9 0.96 (0.37-2.48) 1.14 (0.44-3.00) 
3rd tertile (22.6-59.8%)  1.1 (48) 2.3 8.9 0.26 (0.06-1.08) 0.27 (0.06-1.18) 
Total  2.5 (106) 3.6 6.3 0.58 (0.30-1.11) 0.60 (0.31-1.17) 
p for interaction - - - 0.26 0.28 
Non-CVD death  
    
1st tertile (2-14.5%)  0.9 (37) 5.0 6.4 0.78 (0.30-2.00) 0.85 (0.33-2.18) 
2nd tertile (14.5-22.6%) 44 (1.0) 6.8 7.4 0.91 (0.39-2.16) 1.12 (0.46-2.73) 
3rd tertile (22.6-59.8%)  1.8 (77) 3.5 14.5 0.24 (0.08-0.77) 0.29 (0.09-0.96) 
Total  3.7 (158) 5.1 9.5 0.53 (0.31-0.93) 0.61 (0.35-1.06) 
p for interaction - - - 0.13 0.17 
LLT: lipid-lowering treatment, CVD: cardiovascular disease. * Age, sex, family history of 
CVD, non-HDL-C, diabetes, anti-platelet use, clustering effect by general practice, number of 
assigned in-trial BP lowering drugs. Bold p<0.05. 
Association of LLT and mortality in a subgroup by 5-year estimated CVD risk  
In the subgroup analysis by estimated absolute CVD risk at baseline (Tables 
3 and 4), heterogeneity was found for short-term all-cause mortality, but no other 
12 
 
outcomes. In the highest risk tertile, LLT group had a reduced risk of short-term all-
cause mortality (HR 0.32, 95% CI 0.14-0.75) with p for interaction of 0.02, compared 
to the low and moderate risk tertiles. There was no effect seen in other outcomes in 
the short or long-term.  
Sensitivity analysis 
 In subgroup analyses stratified by age, sex and diabetes status at baseline (Table 1 
and 2 in Supplementary), regarding long-term and short-term associations between 
LLT and mortality outcomes, the associations were not statistically different among 
stratified subgroups.  In a further adjusted model, we added characteristics that were 
statistically different (W-H ratio and previous BP lowering treatment) between the 
LLT group, systolic BP and diastolic BP at randomization in the adjusted model. The 
results were similar to the adjusted model, and no substantial difference was 
recorded. 
Discussion 
In this post-hoc analysis of ANBP2, we found a positive association between 
LLT with long-term all-cause, non-CVD and cancer mortality, but the protective 
association with CVD mortality did not reach statistical significance. For short-term 
outcomes, no significant association was recorded, although the magnitudes of the 
associations (HRs) were similar to the long-term effects.  
Our long-term findings are consistent with the long-term ASCOT-LLA trial 31 
and a 7.3-year observational study 23. All three studies found a significant reduction 
in all-cause mortality and a non-significant reduction in CVD mortality. Surprisingly, 
similar to our study, ASCOT-LLA also observed a significant benefit on long-term 
non-CVD deaths (HR 0.85, 95%CI 0.73-0.99). Our study recorded a substantial 
benefit of LLT on cancer deaths, whereas ASCOT-LLA reported a non-significant 
effect on cancer deaths (HR 0.92, 95%CI 0.76-1.12), but a significant effect on 
deaths related to infectious or respiratory diseases (HR 0.64, 95% CI 0.42-0.97). The 
ANBP2 study did not record these outcomes, so we were unable to include these in 
this analysis. A limitation of our findings is that cancer deaths in both the short- and 
long-term may be confounded by the status of diagnosed cancer at entry. If the 
prevalence of diagnosed cancer at study entry were equally distributed between LLT 
and no LLT group, our results would support findings from previous studies showing 
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a substantial reduction of cancer-related deaths by statin treatment in participants 
either with pre-existing cancer or no cancer 32,33. In contrast, two meta-analyses 5,34 
of large randomised controlled trials showed no beneficial effect of statins on cancer-
related deaths. Yet, most of these RCTs had a high proportion of participants with 
previous CVD.  
In terms of the short-term outcomes, our findings on all-cause and CVD 
mortality are consistent with a previous meta-analysis by Savarese 21  who reported 
a non-significant effect of LLT on all-cause mortality with an RR 0.94 (95% CI 0.86-
1.04; p=0.21) and on CVD mortality with an RR 0.91 (95% CI 0.69-1.20; p=0.49) with 
a mean follow-up of 3.5 years  (range: 1 to 5.2 years). However, in our study, the 
protective association for all-cause mortality reached statistical significance in the 
long-term analysis with the median follow-up time of 10.8 years, suggesting that 
differences in mortality may take longer to accrue. 
In the subgroup analysis by CVD risk,  LLT showed a greater effect on short-
term all-cause mortality in the highest risk tertile, compared to other lower risk 
groups. We did not find any significant difference in the low or moderate risk groups 
regarding other trial endpoints. In contrast to our results, the Cholesterol Treatment 
Trialists (CTT)’  Collaborators 5  observed a substantial reduction of all-cause 
mortality on the total cohort 0.91 (95%CI 0.85-0.97) but a non-statistically significant 
heterogeneity (p for trend=0.2) among risk subgroups (5-year risk at baseline <5%, 
≥5% and <10%, ≥10% and <20%, ≥20% and <30%, ≥30%). The CTT meta-analysis 
included participants at both middle and old age. 
 
Limitations 
Due to the nature of the post-hoc observational design, our findings are open 
to residual confounding, and thus should be interpreted with caution. The results are 
also only based on one study, so are limited by low power. Another limitation of our 
study is missing details of LLT at baseline and in the post-trial period including 
reason for prescription, dose, duration and adherence to treatment. Compared to the 
‘no LLT’ group, LLT participants had a substantially higher total cholesterol and were 
more likely to have previous BP lowering and antiplatelet use, to be diabetic and to 
have a family history of CVD suggesting that they were at higher underlying baseline 
risk. Covariate adjustment has limited ability to control for ‘confounding by indication’. 
In the subgroup analysis by estimated CVD risk, age, sex and diabetes at baseline 
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(Supplementary table 1), the magnitudes of the association between LLT and 
mortality were similar in stratified groups, except that the association between LLT 
and short-term all-cause mortality varied according to estimated CVD risk. The 
association between LLT and other short-term or long-term mortality was found to be 
independent of age, sex, diabetes and estimated CVD risk. Furthermore, 
confounding by indication would be expected to bias in favor of higher mortality in 
the LLT group. A final point is that the risk algorithm is for untreated populations in 
both groups, but underestimation should affect those in the LLT group to a greater 
extent as they were on lipid-lowering therapy. 
In conclusion, our study supports the early use of LLT in those 65 years or 
over due to the association with long-term benefits on all-cause mortality, although 
the short-term benefits are likely to be evident only in the high-risk population. The 
findings suggest that the mortality benefit of LLT for the elderly may take longer to 
become evident. 
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